These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 15584769)

  • 41. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
    Andrade C
    J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.
    Fineberg NA; Reghunandanan S; Brown A; Pampaloni I
    Aust N Z J Psychiatry; 2013 Feb; 47(2):121-41. PubMed ID: 23125399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
    Glick ID; Poyurovsky M; Ivanova O; Koran LM
    J Clin Psychiatry; 2008 Dec; 69(12):1856-9. PubMed ID: 19026264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induced Obsessive Compulsive Symptoms (OCS) in schizophrenia patients under Atypical 2 Antipsychotics (AAPs): review and hypotheses.
    Grillault Laroche D; Gaillard A
    Psychiatry Res; 2016 Dec; 246():119-128. PubMed ID: 27690134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
    Levy E; Margolese HC; Sultan S; Chouinard G
    Can J Psychiatry; 2003 Nov; 48(10):709-10. PubMed ID: 14674056
    [No Abstract]   [Full Text] [Related]  

  • 47. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
    Del Casale A; Sorice S; Padovano A; Simmaco M; Ferracuti S; Lamis DA; Rapinesi C; Sani G; Girardi P; Kotzalidis GD; Pompili M
    Curr Neuropharmacol; 2019; 17(8):710-736. PubMed ID: 30101713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Schizophrenia and obsessive-compulsive disorder.
    Devulapalli K; Nasrallah HA
    Am J Psychiatry; 2010 Nov; 167(11):1407-8. PubMed ID: 21041254
    [No Abstract]   [Full Text] [Related]  

  • 51. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
    Kim SW; Shin IS; Kim JM; Youn T; Yang SJ; Hwang MY; Yoon JS
    Clin Neuropharmacol; 2009; 32(4):224-6. PubMed ID: 19644229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.
    Denys D; Zohar J; Westenberg HG
    J Clin Psychiatry; 2004; 65 Suppl 14():11-7. PubMed ID: 15554783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates.
    Baytunca B; Kalyoncu T; Ozel I; Erermiş S; Kayahan B; Öngur D
    Clin Neuropharmacol; 2017; 40(6):243-245. PubMed ID: 28976410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.
    Szechtman H; Harvey BH; Woody EZ; Hoffman KL
    Pharmacol Rev; 2020 Jan; 72(1):80-151. PubMed ID: 31826934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study.
    Schirmbeck F; Rausch F; Englisch S; Eifler S; Esslinger C; Meyer-Lindenberg A; Zink M
    J Psychopharmacol; 2013 Apr; 27(4):349-57. PubMed ID: 23095245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Obsessive-compulsive disorder (OCD) with psychotic symptoms and response to treatment with SSRI.
    Sievers M; Sato T; Möller HJ; Bottlender R
    Pharmacopsychiatry; 2005 Mar; 38(2):104-5. PubMed ID: 15744638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Obsessive-compulsive symptoms in schizophrenia].
    Kayahan B; Oztürk O; Veznedaroğlu B
    Turk Psikiyatri Derg; 2005; 16(3):205-15. PubMed ID: 16180153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD.
    Biria M; Huang FX; Worbe Y; Fineberg NA; Robbins TW; Fernandez-Egea E
    Eur Neuropsychopharmacol; 2019 Aug; 29(8):905-913. PubMed ID: 31303266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of obsessive-compulsive disorder comorbidity and obsessive-compulsive symptom dimensions in patients with schizophrenia.
    Kokurcan A; Şafak Y
    Saudi Med J; 2020 Mar; 41(3):275-282. PubMed ID: 32114600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.